PharmiWeb

Leqembi® (lecanemab) long-term 36-month open-label extension data from post-hoc sub-group analysis of ApoE ε4 non-carriers and heterozygotes presented at Alzheimer’s ...

The treatment also reduced the risk of progression to the next stage of Alzheimer’s disease by 28% (95% CI: 0.59, 0.87) over 36 months compared to the ADNI cohort, as measured by CDR-SB 1 These data ...
Medscape

Lecanemab Preserves Memory Over 4 Years in Early Alzheimer’s

Continuous treatment with lecanemab (Leqembi, Eisai/Biogen) demonstrated sustained disease-modifying benefit over 4 years in patients with early-stage Alzheimer’s disease (AD) enrolled in the ...
Healio

Data support early, continued lecanemab dosing for Alzheimer’s

Please provide your email address to receive an email when new articles are posted on . Continued lecanemab treatment linked to significant disease-modifying effects. No new safety signals were ...
MedPage Today

Alzheimer's Lecanemab Treatment Up to 36 Months Supported by Extension Study

SAN DIEGO -- Biomarker and cognitive data supported treatment with the anti-amyloid agent lecanemab (Leqembi) for up to 36 months in early Alzheimer's disease, initial findings from the CLARITY AD ...
Nasdaq

Eisai Presents Late-Breaker Updates On Lecanemab Clinical, Biomarker And Safety Data From Phase 2b Study Core And Open-Label Extension Across Five Years At Clinical Trials On ...

TOKYO and CAMBRIDGE, Mass., Nov. 10, 2021 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate ...
The American Journal of Managed Care

FDA Approves New Maintenance Dosing for Lecanemab to Treat Early-Stage Alzheimer Disease

Lecanemab's maintenance dosing regimen is now approved for early-stage Alzheimer's, transitioning from biweekly to once every four weeks after 18 months. Phase 2 and 3 trials confirmed lecanemab's ...